Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2021
Estimated savings from international reference pricing for prescription drugs
10 September 2021 - High prescription drug prices have important implications for health care spending, patient financial burden, and adherence. ...
Posted by Michael Wonder on 05 Aug 2021
U.S. health care system ranks last among 11 high income countries, researchers say
5 August 2021 - The United States has the worst health care system overall among 11 high income countries, even ...
Posted by Michael Wonder on 01 Jul 2021
Analysis of launch and post-approval cancer drug pricing, clinical benefit, and policy implications in the US and Europe
1 June 2021 - In this economic evaluation of the US compared with 3 European countries, launch prices of cancer drugs ...
Posted by Michael Wonder on 31 May 2021
State slower to ‘adopt new drugs’ than most of western Europe
31 May 2021 - Medicines regularly not worth approving at asking price. ...
Posted by Michael Wonder on 31 May 2021
External reference pricing: the drug pricing reform America needs?
27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...
Posted by Michael Wonder on 30 Apr 2021
Americans paid two to four times as much for some drugs as in three other countries
28 April 2021 - Amid national angst over the cost of prescription drugs, a new analysis finds that U.S. consumers ...
Posted by Michael Wonder on 12 Apr 2021
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
Posted by Michael Wonder on 03 Nov 2020
Regulatory policy may not stop comparative efficacy trials
4 November 2020 - The way Sarfaraz K. Niazi, looks at it, doing comparative efficacy studies in humans to confirm that ...
Posted by Michael Wonder on 08 Oct 2020
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
7 October 2020 - The investigators of the study set out to characterise the therapeutic value of new drugs approved ...
Posted by Michael Wonder on 28 Sep 2020
Sophisticated purchasing of pharmaceuticals: learning from other countries
28 September 2020 - In 2019 and early 2020, drug pricing in the United States was a top concern of ...
Posted by Michael Wonder on 15 Sep 2020
FDA publishes comparative performance data for COVID-19 molecular diagnostic tests
15 September 2020 - Today, the U.S. FDA published comparative performance data for some authorised COVID-19 molecular diagnostic tests. ...
Posted by Michael Wonder on 05 Sep 2020
Biocon, Mylan launch Semglee and seek biosimilar, interchangeable status
31 August 2020 - For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to ...
Posted by Michael Wonder on 05 Sep 2020
International reference pricing: discounts down under far surpass U.S. drug price concessions
1 September 2020 - At 30,000 feet, the view of Australia’s healthcare system does not look too different from our own ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 19 Jul 2020
PBAC asks Roche for another comparison for Tecentriq
20 July 2020 - The submission requested a PBS (Section 100) listing for atezolizumab for use in combination with taxane chemotherapy ...